Title Adherencija u uzimanju metformina i pojavnost nuspojava u bolesnika sa šećernom bolešću tipa 2
Title (english) Adherence in metformin taking and occurrence of side effects in patients with type 2 diabetes
Author Josip Baković
Mentor Mladen Krnić (mentor)
Committee member Tina Tičinović Kurir (predsjednik povjerenstva)
Committee member Ivana Pavlinac Dodig (član povjerenstva)
Committee member Joško Božić (član povjerenstva)
Granter University of Split School of Medicine Split
Defense date and country 2021, Croatia
Scientific / art field, discipline and subdiscipline BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Internal Medicine
Abstract Ciljevi istraživanja: Cilj ovog istraživanja je utvrditi adherenciju pri uzimanju metformina i pojavnost nuspojava kod bolesnika sa šećernom bolešću tipa 2 u ovisnosti o adherenciji te utvrditi povezanost učestalosti nuspojava s propisivačem terapije, informiranosti o šećernoj bolesti, regulaciji glikemije te vrsti pripravka metformina.
Ispitanici i metode: U svrhu ovog presječnog istraživanja ispitanici su anketirani u izravnom fizičkom kontaktu u čekaonici Regionalnog centra za
... More endokrinologiju, dijabetologiju i poremećaje metabolizma KBC-a Split, dijelu ispitanika podaci su uzeti iz registra Centra te su zatim anketirani telefonom, a manji dio ispitanika prikupljen je iz ordinacija obiteljske medicine. U ovo istraživanje uključeno je 107 bolesnika.
Rezultati: Gledajući vrijeme uzimanja terapije u odnosu na jelo, najviše ispitanika 70 (65%) uzima terapiju poslije jela (ispravno), 12% uz jelo (prihvatljivo), 20% ispitanika uzima prije jela, a 3% u isto vrijeme neovisno o jelu (neispravan način uzimanja). Ukupno 74 (69%) ispitanika pravilno uzima i ne preskače lijek te su u potpunosti adherentni, dok 33 (31%) ispitanika ne uzima pravilno lijek ili ga preskače. Dvadeset osam (26,2%) ispitanika je navelo da ima nuspojave prilikom uzimanja koje vezuju uz uzimanje aktualne terapije dok kod preostalih 79 (73,8%) ispitanika nije bilo nikakvih nuspojava. Od adherentnih bolesnika (ukupno 74, odnosno 69%) njih 8 (10%) ima prisutne nuspojave. U skupini neadherentnih (ukupno 33, odnosno 31%) nuspojave se javljaju u 20 (60%) bolesnika) (p<0.001). Postoji značajna povezanost pojavnosti nuspojava s informiranošću bolesnika: informiranost o šećernoj bolesti (p=0,009) informiranost o svrsi liječenja (p=0,036), informiranost o načinu uzimanja terapije (p=0,005). Informiranost o nuspojavama nije statistički značajno povezana s nuspojavama (p=0,092). Značajna povezanost nuspojava primjećuje se i u odnosu na prosječne i zadnje izmjerene
vrijednosti glukoze u plazmi natašte (p=0,049, odnosno 0,030) i postprandijalno (p=0,030, odnosno 0,031), dok vrijednost HbA1c (p=0,106) nije pokazala
statistički značajnu razliku u odnosu na učestalost nuspojava. Nema značajne povezanosti nuspojava s vrstom lijeka koji sadržava metformin i propisivačem terapije.
Zaključak: Adherencija u uzimanju terapije metforminom ili pripravcima koji sadržavaju metformin je relativno loša (69%). Bolesnici koji neredovito i nepravilno uzimaju terapiju imaju veću učestalost nuspojava i to za 6 puta. Ne postoji statistički značajna učestalost nuspojava u ovisnosti o propisivaču terapije te o pripravku metformina, neovisno o dozi. Učestalost nuspojava je češća kod bolesnika koji su lošije informirani o šećernoj bolesti te kod onih čija je regulacije glikemije loša. Less
Abstract (english) Research objectives: This study aimed was to determine the adherence of metformin and the incidence of side effects in patients with type 2 diabetes depending on adherence and to determine the relationship between the frequency of side effects with the prescriber, diabetes awareness, glycemic control and the type of metformin.
Subjects and methods: For this cross-sectional study, respondents were interviewed in direct physical contact in the waiting room of the Regional Center
... More for Endocrinology, Diabetology and Metabolic Disorders, University Hospital of Split, some respondents were taken from the Center's register and then interviewed by phone, a smaller proportion of respondents were taken from a family medicine practice. 107 patients were included in this study.
Results: Looking at the time of taking therapy in relation to the meal, most respondents 70 (65%) take therapy after meals (correctly), 12% with meals (acceptable). 20% of respondents take before meals, and 3% at the same time regardless of meals (incorrect way). A total of 74 (69%) respondents take and do not skip the medication correctly and are completely adherent, while 33 (31%) respondents do not take the medication correctly or skip it. Twenty-eight (26.2%) subjects reported having side effects when taking a therapy while the remaining 79 (73.8%) subjects had no side effects. Of the adherent patients (a total of 74 and 69%, respectively), 8 (10%) had side effects. In the group of non-adherent (33 and 31%, respectively) side effects occur in 20 (60%) patients) (p <0.001). There is a significant correlation between the occurrence of side effects and patient information: information about diabetes (p = 0.009), information about the purpose of treatment (p = 0.036), information about how to take therapy (p = 0.005).
Conclusion: Adherence to metformin therapy or metformin-containing preparations is relatively poor (69%). Patients who take therapy irregularly and incorrectly have a higher frequency of side effects by 6 times. There is no statistically significant difference in frequency of adverse reactions depending on the prescriber and the formulation of metformin. The incidence of side effects is more common in patients who are less informed about diabetes and in those whose glycemic regulation is poor. Less
Keywords
Šećerna bolest tipa 2
Metformin-štetni učinci
Pridržavanje liječenju
Keywords (english)
Diabetes Mellitus Type 2
Metformin-adverse effects
Medication Adherence
Language croatian
URN:NBN urn:nbn:hr:171:081203
Study programme Title: Medicine Study programme type: university Study level: integrated undergraduate and graduate Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resource Text
File origin Born digital
Access conditions Open access Embargo expiration date: 2023-10-15
Terms of use
Created on 2021-10-15 11:10:01